5.80
Schlusskurs vom Vortag:
$5.66
Offen:
$5.61
24-Stunden-Volumen:
1.10M
Relative Volume:
1.41
Marktkapitalisierung:
$318.41M
Einnahmen:
$124.00K
Nettoeinkommen (Verlust:
$-49.99M
KGV:
-3.432
EPS:
-1.69
Netto-Cashflow:
$-31.03M
1W Leistung:
+15.54%
1M Leistung:
+14.40%
6M Leistung:
-0.85%
1J Leistung:
+25.81%
Candel Therapeutics Inc Stock (CADL) Company Profile
Firmenname
Candel Therapeutics Inc
Sektor
Branche
Telefon
617-916-5445
Adresse
117 KENDRICK STREET, NEEDHAM
Vergleichen Sie CADL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
CADL
Candel Therapeutics Inc
|
5.80 | 310.72M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-28 | Eingeleitet | Stephens | Overweight |
| 2025-09-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-06-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-20 | Eingeleitet | Citigroup | Buy |
| 2025-02-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-02-07 | Eingeleitet | BofA Securities | Buy |
| 2022-12-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-08-23 | Eingeleitet | Credit Suisse | Outperform |
| 2021-08-23 | Eingeleitet | Jefferies | Buy |
| 2021-08-23 | Eingeleitet | UBS | Buy |
Alle ansehen
Candel Therapeutics Inc Aktie (CADL) Neueste Nachrichten
Citi Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛
Candel Therapeutics (NASDAQ:CADL) Shares Little Changed on Clinical-Stage Progress - Kalkine Media
Stephens Reaffirms Overweight Rating for Candel Therapeutics (NASDAQ:CADL) - MarketBeat
Candel Therapeutics, Inc. (NASDAQ:CADL) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
CADL: CAN-2409's phase 3 success and strong market outlook drive launch readiness and pipeline expansion - TradingView
CADL: CAN-2409's phase III success and strong market readiness position it for rapid adoption and growth - TradingView
CADL: Late-stage immunotherapy programs advance toward commercialization and regulatory milestones - TradingView
Candel Therapeutics, Inc. Hosts R&D Day Highlighting Viral Immunotherapy Advances - TradingView
How Candel Therapeutics Inc. stock trades before earningsJuly 2025 Sentiment & AI Driven Stock Price Forecasts - Newser
Is Candel Therapeutics Inc. stock recession proof2025 Price Targets & Long-Term Capital Growth Strategies - Newser
Candel Therapeutics (CADL) Stock Analysis Report | Financials & Insights - Benzinga
Is Candel Therapeutics Inc. stock attractive after correctionWeekly Volume Report & AI Forecast for Swing Trade Picks - Newser
Is Candel Therapeutics Inc. stock resilient to inflationPortfolio Update Summary & Safe Capital Investment Plans - Newser
Candel: lighting the path to a brighter future for patients with solid tumors - Nature
Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know - MSN
Candel Therapeutics Stock Headed For 20% Weekly Gains: Retail Over The Moon With BofA's 'Buy' Call - MSN
Candel Therapeutics stock price target raised to $14 by Freedom Capital - Investing.com Nigeria
Will Candel Therapeutics Inc. stock gain from strong economy2025 Price Targets & High Accuracy Trade Alerts - newser.com
What technical models suggest about Candel Therapeutics Inc.’s comebackIndex Update & Safe Entry Zone Tips - newser.com
Why Candel Therapeutics Inc. stock could see breakout soon2025 Earnings Impact & Verified Swing Trading Watchlists - newser.com
How geopolitical tensions affect Candel Therapeutics Inc. stockPortfolio Update Report & Stepwise Trade Signal Guides - newser.com
How Candel Therapeutics Inc. stock performs in stagflationJuly 2025 Earnings & Technical Buy Zone Confirmations - newser.com
Candel Therapeutics Inc. (CADL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is Candel Therapeutics Inc. building a consolidation baseShare Buyback & AI Powered Market Trend Analysis - newser.com
Candel Therapeutics to host virtual Research & Development event - Proactive Investors
Candel Therapeutics, Inc. Announces Virtual Research and Development Day for December 5, 2025 - Quiver Quantitative
Candel Therapeutics to Host Virtual R&D Event on December 5, 2025 - The Manila Times
Candel Therapeutics (Nasdaq: CADL) Sets Virtual R&D Event on Immuno-Oncology, CAN-2409 and CAN-3110 - Stock Titan
Will Candel Therapeutics Inc. stock benefit from automationJuly 2025 Action & High Accuracy Trade Signal Alerts - newser.com
How Candel Therapeutics Inc. stock compares to growth peersJuly 2025 Highlights & Verified Entry Point Signals - newser.com
Citigroup Cuts Candel Therapeutics (NASDAQ:CADL) Price Target to $24.00 - MarketBeat
What’s next for Candel Therapeutics Inc. stock price2025 Price Action Summary & Safe Entry Zone Tips - newser.com
Will Candel Therapeutics Inc. see short term momentumWeekly Stock Summary & Consistent Profit Trade Alerts - newser.com
Analysts’ Top Healthcare Picks: Candel Therapeutics (CADL), Pfizer (PFE) - The Globe and Mail
Finanzdaten der Candel Therapeutics Inc-Aktie (CADL)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):